Physician profile
Robert Goldstein
NPI 1558475376
$596.90
in general payments reported to CMS, 2019-2025
12 companies · $145 in 2025
The $145 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $46.00 · 2021: $137 · 2022: $88.54 · 2023: $135 · 2024: $45.52 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $300 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.42 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $268.70 | 2020-2025 | Grafix Pl, Collagenase Santyl |
| Lilly USA, LLC | $98.24 | 2022-2025 | Taltz, Ebglyss |
| Janssen Biotech, INC. | $43.50 | 2023-2025 | Tremfya |
| Mentor Worldwide LLC | $35.53 | 2021-2023 | Mentor Memorygel Resterilizable Gel Sizer |
| Merz North America, INC. | $32.44 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $22.62 | 2022 | |
| Galderma Laboratories, L.P. | $18.29 | 2024 | |
| Leo Pharma INC. | $18.22 | 2025 | Adbry |
| Cipher Pharmaceuticals US LLC | $18.05 | 2025 | Spinosad, Natroba |
| Integra Lifesciences Corporation | $15.72 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Abbvie INC. | $14.43 | 2023 | |
| Acelrx Pharmaceuticals, INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.